Tumor-related HSP70 released after cryo-thermal therapy targeted innate immune initiation in the antitumor immune response

Reference

• Li X, Yang J, Peng L, et al. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res Treat. 2017;161(2):279–287.
   PubMed Web of Science ®Google Scholar
• Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3(11):991–998.
   PubMed Web of Science ®Google Scholar
• Garg AD, Dudek AM, Agostinis P. Cancer immunogenicity, danger signals, and DAMPs: what, when, and how? Biofactors. 2013;39(4):355–367.
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol. 2006;6(10):715–727.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vacchelli E, Bravo-San Pedro JM, et al. Classification of current anticancer immunotherapies. Oncotarget. 2014;5(24):12472–12508.
   PubMed Web of Science ®Google Scholar
• Blankenstein T, Coulie PG, Gilboa E, et al. The determinants of tumour immunogenicity. Nat Rev Cancer. 2012;12(4):307–313.
   PubMed Web of Science ®Google Scholar
• Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol. 1994;12:991–1045.
   PubMed Web of Science ®Google Scholar
• Rock KL, Hearn A, Chen CJ, et al. Natural endogenous adjuvants. Springer Semin Immunopathol. 2005;26(3):231–246.
   PubMed Web of Science ®Google Scholar
• Garg AD, Krysko DV, Vandenabeele P, et al. DAMPs and PDT-mediated photo-oxidative stress: exploring the unknown. Photochem Photobiol Sci. 2011;10(5):670–680.
   PubMed Web of Science ®Google Scholar
• Garg AD, Nowis D, Golab J, et al. Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation. Biochim Biophys Acta. 2010;1805(1):53–71.
   PubMed Web of Science ®Google Scholar
• Asea A, Kraeft SK, Kurt-Jones EA, et al. HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat Med. 2000;6(4):435–442.
   PubMed Web of Science ®Google Scholar
• Gold LI, Eggleton P, Sweetwyne MT, et al. Calreticulin: non-endoplasmic reticulum functions in physiology and disease. FASEB J. 2010;24(3):665–683.
   PubMed Web of Science ®Google Scholar
• Inoue H, Tani K. Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments. Cell Death Differ. 2014;21(1):39–49.
   PubMed Web of Science ®Google Scholar
• Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13(1):54–61.
   PubMed Web of Science ®Google Scholar
• Müller S, Ronfani L, Bianchi ME. Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function. J Intern Med. 2004;255(3):332–343.
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galluzzi L, Kepp O, et al. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51–72.
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Kepp O, Kroemer G. Decoding cell death signals in inflammation and immunity. Cell. 2010;140(6):798–804.
   PubMed Web of Science ®Google Scholar
• Garg AD, Martin S, Golab J, et al. Danger signalling during cancer cell death: origins, plasticity and regulation. Cell Death Differ. 2014;21(1):26–38.
   PubMed Web of Science ®Google Scholar
• Chen G, Ward MF, Sama AE, et al. Extracellular HMGB1 as a proinflammatory cytokine. J Interferon Cytokine Res. 2004;24(6):329–333.
   PubMed Web of Science ®Google Scholar
• Tang D, Kang R, Coyne CB, et al. PAMPs and DAMPs: signal 0s that spur autophagy and immunity. Immunol Rev. 2012;249(1):158–175.
   PubMed Web of Science ®Google Scholar
• Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13(4):227–242.
   PubMed Web of Science ®Google Scholar
• Yatim N, Cullen S, Albert ML. Dying cells actively regulate adaptive immune responses. Nat Rev Immunol. 2017;17(4):262–275.
   PubMed Web of Science ®Google Scholar
• Zhang K, Zou J, He K, et al. Study of enhanced radiofrequency heating by pre-freezing tissue. Int J Hyperthermia. 2018;35(1):79–89.
   PubMed Web of Science ®Google Scholar
• Zhu J, Zhang Y, Zhang A, et al. Cryo-thermal therapy elicits potent anti-tumor immunity by inducing extracellular Hsp70-dependent MDSC differentiation. Sci Rep. 2016;6:27136.
   PubMed Web of Science ®Google Scholar
• He K, Liu P, Xu LX. The cryo-thermal therapy eradicated melanoma in mice by eliciting CD4+ T-cell-mediated antitumor memory immune response. Cell Death Dis. 2017;8(3):e2703.
   PubMed Web of Science ®Google Scholar
• He K, Jia S, Lou Y, et al. Cryo-thermal therapy induces macrophage polarization for durable anti-tumor immunity. Cell Death Dis. 2019;10(3):216.
   PubMed Web of Science ®Google Scholar
• Shen Y, Liu P, Zhang A, et al. Study on tumor microvasculature damage induced by alternate cooling and heating. Ann Biomed Eng. 2008;36(8):1409–1419.
   PubMed Web of Science ®Google Scholar
• Hernandez C, Huebener P, Schwabe RF. Damage-associated molecular patterns in cancer: a double-edged sword. Oncogene. 2016;35(46):5931–5941.
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12(4):253–268.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Marchesi F, Malesci A, et al. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14(7):399–416.
   PubMed Web of Science ®Google Scholar
• Chen C, Zhang A, Cai Z, et al. Design of microprobe for accurate thermal treatment of tumor. Cryo Lett. 2011;32(3):275–286.
   PubMed Web of Science ®Google Scholar
• Cai Z, Song M, Sun J, et al. Design of a new probe for tumor treatment in the alternate thermal system based on numerical simulation. Conf Proc IEEE Eng Med Biol Soc. 2011;2011:6874–6877.
   PubMedGoogle Scholar
• Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141(1):39–51.
   PubMed Web of Science ®Google Scholar
• Bellora F, Castriconi R, Dondero A, et al. TLR activation of tumor-associated macrophages from ovarian cancer patients triggers cytolytic activity of NK cells. Eur J Immunol. 2014;44(6):1814–1822.
   PubMed Web of Science ®Google Scholar
• Vatner RE, Janssen EM. STING, DCs and the link between innate and adaptive tumor immunity. Mol Immunol. 2019;110:13–23.
   PubMed Web of Science ®Google Scholar
• Moynihan KD, Opel CF, Szeto GL, et al. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat Med. 2016;22(12):1402–1410.
   PubMed Web of Science ®Google Scholar
• Ellmark P, Mangsbo SM, Furebring C, et al. Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation. Cancer Immunol Immunother. 2017;66(1):1–7.
   PubMed Web of Science ®Google Scholar
• Patidar A, Selvaraj S, Sarode A, et al. DAMP-TLR-cytokine axis dictates the fate of tumor. Cytokine. 2018;104:114–123.
   PubMed Web of Science ®Google Scholar
• Garg AD, Agostinis P. Cell death and immunity in cancer: from danger signals to mimicry of pathogen defense responses. Immunol Rev. 2017;280(1):126–148.
   PubMed Web of Science ®Google Scholar
• Krombach J, Hennel R, Brix N, et al. Priming anti-tumor immunity by radiotherapy: dying tumor cell-derived DAMPs trigger endothelial cell activation and recruitment of myeloid cells. Oncoimmunology. 2019;8(1):e1523097.
   PubMed Web of Science ®Google Scholar
• Dasgupta S, Bayry J, Lacroix-Desmazes S, et al. Human mannose receptor (CD206) in immune response: novel insights into vaccination strategies using a humanized mouse model. Expert Rev Clin Immunol. 2007;3(5):677–681.
   PubMedGoogle Scholar
• Watts C, West MA, Zaru R. TLR signalling regulated antigen presentation in dendritic cells. Curr Opin Immunol. 2010;22(1):124–130.
   PubMed Web of Science ®Google Scholar
• Płóciennikowska A, Hromada-Judycka A, Borzęcka K, et al. Co-operation of TLR4 and raft proteins in LPS-induced pro-inflammatory signaling. Cell Mol Life Sci. 2015;72(3):557–581.
   PubMed Web of Science ®Google Scholar
• Josephs SF, Ichim TE, Prince SM, et al. Unleashing endogenous TNF-alpha as a cancer immunotherapeutic. J Transl Med. 2018;16(1):242.
   PubMed Web of Science ®Google Scholar
• de Matos LG, Cândido EB, Vidigal PV, et al. Association between Toll-like receptor and tumor necrosis factor immunological pathways in uterine cervical neoplasms. Tumori. 2017;103(1):81–86.
   PubMed Web of Science ®Google Scholar
• Shi L, Wang J, Ding N, et al. Inflammation induced by incomplete radiofrequency ablation accelerates tumor progression and hinders PD-1 immunotherapy. Nat Commun. 2019;10(1):5421.
   PubMed Web of Science ®Google Scholar
• Merlo LM, Mandik-Nayak L. IDO2: a pathogenic mediator of inflammatory autoimmunity. Clin Med Insights Pathol. 2016;9(Suppl 1):21–28.
   PubMedGoogle Scholar
• Merlo LMF, Pigott E, DuHadaway JB, et al. IDO2 is a critical mediator of autoantibody production and inflammatory pathogenesis in a mouse model of autoimmune arthritis. J Immunol. 2014;192(5):2082–2090.
   PubMed Web of Science ®Google Scholar
• Waldmann TA, Miljkovic MD, Conlon KC. Interleukin-15 (dys)regulation of lymphoid homeostasis: implications for therapy of autoimmunity and cancer. J Exp Med. 2020;217(1):e20191062.
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI. Myeloid-derived suppressor cells. Cancer Immunol Res. 2017;5(1):3–8.
   PubMed Web of Science ®Google Scholar